Connect with us

Business

Trump’s 50% Tariff On India To Leave Americans Paying More, Here’s What Gets Costlier

Published

on

Trump’s 50% Tariff On India To Leave Americans Paying More, Here’s What Gets Costlier


Last Updated:

Donald Trump Tariffs: Trump’s 50 percent tariffs on Indian imports, sharply raises US prices on textiles, jewellery, shrimp, chemicals and more, impacting consumers, manufacturers.

font
Donald Trump India Tariffs: A person shops in a supermarket as inflation affected consumer prices in Manhattan, New York City, US. (IMAGE: REUTERS FILE)

Donald Trump India Tariffs: A person shops in a supermarket as inflation affected consumer prices in Manhattan, New York City, US. (IMAGE: REUTERS FILE)

Donald Trump India Tariffs: The United States is bracing for a wave of price increases as US President Donald Trump’s administration is set to impose sweeping tariffs on Indian imports to the country, doubling duties to 50 per cent in retaliation for New Delhi’s purchase of Russian oil. The move, covering $48 billion worth of Indian goods, is one of the most punitive tariff actions US has ever taken against an ally.

The sectors most affected include textiles, gems and jewellery, shrimp, carpets, handicrafts, furniture, leather, organic chemicals and machinery.

That means everyday items for American households, ranging from linens, rugs and apparel to jewellery, mattresses and shrimp, will now carry a sharply higher price tag. Diamonds, gold jewellery and household furnishings will attract more than 50 per cent duty, while knitted clothes face nearly 64 per cent.

A Moneycontrol report said that apparel and home textiles face particularly sharp hikes: knitted clothing could see duties near 64 percent, woven garments around 60 percent, and bed linens and towels roughly 59 percent.

Americans who love jewellery will also feel the pinch as diamonds, gold, and other Indian-made ornaments are now subject to more than 52 percent in import duties. Also burdened are leather goods and footwear, a staple in US wardrobes, the news report by the financial news outlet said.

Even non-fashion categories aren’t spared—organic chemicals now face duties up to 54 percent, while mechanical appliances and engineering goods cross the 51 percent threshold, making mid-range equipment markedly less affordable for American buyers. Seafood such as shrimp, another Indian export, will also become costlier and on top of existing anti-dumping duties, the new tariff will push the total levy beyond 33 percent.

Blow to US Manufacturers Too

Tariffs were pitched as a way to protect American manufacturing jobs, but survey data from the Dallas Fed, accessed by broadcaster CNN, shows the opposite effect. Nearly 70 per cent of manufacturers report being hurt by higher tariffs this year, with many passing on costs to industrial and military clients. One Texas furniture maker told the Fed, “We are probably going out of business within 90 days.”

Postal services in Europe and Asia are already suspending shipments to the US after the scrapping of a tariff exemption on low-value packages. That means fewer options for American online shoppers relying on e-commerce platforms like Etsy, Shopify and TikTok Shop.

American Consumers Caught in the Middle

The tariff escalation, which leaves India facing one of the highest US import duties alongside Brazil, may shift supply chains toward competitors like Vietnam, Bangladesh and Mexico. But for US shoppers, the immediate result is fewer choices and higher prices.

“Tariffs will raise input costs for American companies, strain profit margins, and disrupt supply chains with long-term inefficiencies even if the policy is reversed later,” said Professor Trilochan Tripathy of XLRI Jamshedpur while speaking to news agency PTI.

In the short term, American households are set to pay more for Indian goods they rely on.

Economists speaking to the US broadcaster CNN called it “sneakflation”, defining it as small, incremental price hikes that quietly eat into household budgets.

For lower-income Americans, already living paycheck to paycheck, such gradual increases mean tough choices: skipping groceries to pay utility bills or cutting back on healthcare to afford children’s clothes.

From toys and sporting goods to furniture and shrimp cocktails, tariff-driven inflation is expected to spread over the next year. The Federal Reserve Bank of Atlanta noted that both tariff-exposed and non-exposed US businesses plan to raise prices in 2025, raising fears of another inflationary impulse.

authorimg

Shankhyaneel Sarkar

Shankhyaneel Sarkar is a senior subeditor at News18. He covers international affairs, where he focuses on breaking news to in-depth analyses. He has over five years of experience during which he has covered sev…Read More

Shankhyaneel Sarkar is a senior subeditor at News18. He covers international affairs, where he focuses on breaking news to in-depth analyses. He has over five years of experience during which he has covered sev… Read More

News business Trump’s 50% Tariff On India To Leave Americans Paying More, Here’s What Gets Costlier
Disclaimer: Comments reflect users’ views, not News18’s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Read More



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

FDA vaccine head will step down in April after string of controversial decisions

Published

on

FDA vaccine head will step down in April after string of controversial decisions


The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, April 22, 2025.

Nathan Posner | Anadolu | Getty Images

A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the agency following multiple decisions that raised concerns within the industry.

Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesperson confirmed on Friday. It is his second departure from the position: He briefly left the post in July following backlash over his regulatory decisions, and returned only two weeks later in August.

In a post on X, FDA Commissioner Marty Makary said the FDA will appoint a successor before Prasad returns next month to the University of California San Francisco, where he taught before taking the FDA position last year. Makary said Prasad “got a tremendous amount accomplished” during his tenure at the agency.

Prasad’s decision to step down comes after criticism of the FDA mounted within the biotech and pharmaceutical industry and among former health officials. In the past year, the agency has denied or discouraged the approval applications of at least eight drugs, according to RTW Investments, after taking issue with data the companies used to support their applications. The FDA also initially refused to review Moderna’s flu shot before it later reversed course.

All of those companies accused the FDA of reversing previous guidance about the evidence they could use to back their applications, sparking criticism within the industry that an unreliable regulatory process could stifle development of drugs for hard-to-treat diseases.

A former FDA official who spoke to CNBC on the condition of anonymity to speak freely on the issue called the reversals the worst kind of regulatory uncertainty because companies say they are being told one thing and then experience another.

In a statement earlier Friday, an FDA spokesperson said there was “no regulatory uncertainty,” adding the agency “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson said the FDA is “conducting rigorous, independent reviews and not rubber-stamping approvals.”

The most recent controversy came after the FDA discouraged UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease.

The agency, which underwent staff cuts and an overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., has faced broader backlash for its drug and vaccine approvals process. Critics have worried the agency could stifle the development of new treatments and risk the safety of patients.

The Wall Street Journal earlier reported Prasad’s departure.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Business

Oil price at two-year high after Qatar minister warns all Gulf production could stop

Published

on

Oil price at two-year high after Qatar minister warns all Gulf production could stop



Energy Minister Saad al-Kaabi says oil could hit $150 a barrel if the Iran conflict continues over the coming weeks.



Source link

Continue Reading

Business

Govt increases petrol, diesel prices by Rs55 per litre amid Middle East tensions – SUCH TV

Published

on

Govt increases petrol, diesel prices by Rs55 per litre amid Middle East tensions – SUCH TV



The federal government has raised petrol prices by Rs55 per litre as surging global oil prices, fuelled by the US‑Israel war with Iran, put pressure on domestic energy costs.

The announcement was made by Petroleum Minister Ali Pervaiz Malik in a press conference alongside DPM Ishar Dar and Finance Minister Muhammad Aurangzeb.

This marks the first weekly review of fuel prices since regional tensions threatened a major share of global energy flows following the closure of the Strait of Hormuz.

Previously, the federal government adjusted petroleum prices on a fortnightly basis.



Source link

Continue Reading

Trending